FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2577208556> ?p ?o ?g. }

• W2577208556 abstract "Abstract Fungal infections (FI) remain a major threat for patients during allogeneic stem cell transplantation (SCT). There is an ongoing controversy regarding the best fungal prophylaxis. The current study was performed to retrospectively compare three different antifungal medications (itraconazole (ITRA), fluconazole (FLU), and amphotericin B (AMB) preparations) during SCT with regard to FI, survival and complications (toxicity, GVHD, engraftment). 116 children (mean age 10.1 years, female n=48, mean body weight (bw) 27.5 kg) transplanted between March 1998 and August 2003 with complete clinical, microbiological and radiological data were included. Four patients receiving a different antifungal medication (combination therapy ± caspofungin) were excluded. The underlying diseases included acute and chronic leukemias (n=71), inborn metabolic or immunological diseases, lymphomas and bone marrow failure syndromes. In 53 children (46%) a matched family donor was available; in 45 patients (39%) a matched unrelated donor was chosen. In the remaining patients alternative donors (haploidentical, mismatch-related or -unrelated, cord-blood) were selected. Forty children received FLU, 23 patients received AMB-preparations, and 53 children received ITRA. ITRA was given intravenously from day +3 after SCT (10mg/kg bw for 3 days as “loading”, afterwards 5mg/kg bw) until oral medication (ITRA solution) became possible. All prophylactic regimen were continued until day +100 after SCT. In AMB patients FLU was administered after discharge. The three groups did not differ with regard to demographic data, underlying diseases or type of transplantation, only the follow-up period was significantly shorter in the ITRA group. We observed three new FI in the FLU/AMB group (fusariosis n=1, aspergillosis n=2) and one new FI in the ITRA group (candidiasis n=1) (p = 0.377). A change of the antimycotic regimen was necessary in 27/40 (68%) of the FLU, in 21% of the ITRA and in 30% of the AMB patients. Toxicity was minimal in the FLU and ITRA groups and only rarely necessitated a change of the prophylaxis. At day +100 after SCT, 10/63 (16%) of the patients in the FLU/AMB group and 4/53 (8%) in the ITRA group had died (p = 0.139). At the end of the study period (12-31-2004) we observed 17/63 (27%) deaths in the FLU/AMB group compared to 6/53 (8%) in the ITRA group (p &lt; 0.029), with a median follow-up of 5.7 years in the AMB, 4.5 years in the FLU and 2.0 years in the ITRA group. In three children the FI was regarded as the cause of death (not in the candidemia-patient), in the remaining patients relapse (n=5), viral infections (n=6), SCT-related toxicity (n=4) and other infection (n=5) were the cause of death without statistical differences between the groups. The incidence of acute and chronic graft versus host disease (GVHD) differed not significantly between the study groups but the time to engraftment (leukocyte count &gt; 1000/μl) lasted significantly longer in the ITRA group (14.8 days vs. 19.3 days, p &lt; 0.000). Our results indicate that ITRA (oral and intravenous) starting on day 3 after SCT is a safe prophylaxis in pediatric SCT, the analysis of FI is hampered by low numbers. The issues of survival (ITRA group performed better than AMB/FLU) and engraftment (ITRA group longer than AMB/FLU) will be addressed by longer follow-up during ongoing studies." @default.
• W2577208556 created "2017-01-26" @default.
• W2577208556 creator A5012976716 @default.
• W2577208556 creator A5018310059 @default.
• W2577208556 creator A5024722052 @default.
• W2577208556 creator A5045912298 @default.
• W2577208556 creator A5048065837 @default.
• W2577208556 creator A5055400659 @default.
• W2577208556 creator A5060114553 @default.
• W2577208556 creator A5069549958 @default.
• W2577208556 creator A5085036785 @default.
• W2577208556 date "2005-11-16" @default.
• W2577208556 modified "2023-09-27" @default.
• W2577208556 title "Antifungal Prophylaxis with Oral and Intravenous Itraconazole in Pediatric Stem Cell Tansplantation: A Retrospective Comparison with Fluconazole and Amphotericin B-Preparations in 116 Children." @default.
• W2577208556 doi "https://doi.org/10.1182/blood.v106.11.5356.5356" @default.
• W2577208556 hasPublicationYear "2005" @default.
• W2577208556 type Work @default.
• W2577208556 sameAs 2577208556 @default.
• W2577208556 citedByCount "0" @default.
• W2577208556 crossrefType "journal-article" @default.
• W2577208556 hasAuthorship W2577208556A5012976716 @default.
• W2577208556 hasAuthorship W2577208556A5018310059 @default.
• W2577208556 hasAuthorship W2577208556A5024722052 @default.
• W2577208556 hasAuthorship W2577208556A5045912298 @default.
• W2577208556 hasAuthorship W2577208556A5048065837 @default.
• W2577208556 hasAuthorship W2577208556A5055400659 @default.
• W2577208556 hasAuthorship W2577208556A5060114553 @default.
• W2577208556 hasAuthorship W2577208556A5069549958 @default.
• W2577208556 hasAuthorship W2577208556A5085036785 @default.
• W2577208556 hasConcept C126322002 @default.
• W2577208556 hasConcept C141071460 @default.
• W2577208556 hasConcept C16005928 @default.
• W2577208556 hasConcept C2777071850 @default.
• W2577208556 hasConcept C2779548794 @default.
• W2577208556 hasConcept C2779629538 @default.
• W2577208556 hasConcept C2780402444 @default.
• W2577208556 hasConcept C2780651595 @default.
• W2577208556 hasConcept C2781413609 @default.
• W2577208556 hasConcept C2911091166 @default.
• W2577208556 hasConcept C71924100 @default.
• W2577208556 hasConcept C90924648 @default.
• W2577208556 hasConceptScore W2577208556C126322002 @default.
• W2577208556 hasConceptScore W2577208556C141071460 @default.
• W2577208556 hasConceptScore W2577208556C16005928 @default.
• W2577208556 hasConceptScore W2577208556C2777071850 @default.
• W2577208556 hasConceptScore W2577208556C2779548794 @default.
• W2577208556 hasConceptScore W2577208556C2779629538 @default.
• W2577208556 hasConceptScore W2577208556C2780402444 @default.
• W2577208556 hasConceptScore W2577208556C2780651595 @default.
• W2577208556 hasConceptScore W2577208556C2781413609 @default.
• W2577208556 hasConceptScore W2577208556C2911091166 @default.
• W2577208556 hasConceptScore W2577208556C71924100 @default.
• W2577208556 hasConceptScore W2577208556C90924648 @default.
• W2577208556 hasLocation W25772085561 @default.
• W2577208556 hasOpenAccess W2577208556 @default.
• W2577208556 hasPrimaryLocation W25772085561 @default.
• W2577208556 hasRelatedWork W1604943796 @default.
• W2577208556 hasRelatedWork W1969235082 @default.
• W2577208556 hasRelatedWork W2040261410 @default.
• W2577208556 hasRelatedWork W2070743776 @default.
• W2577208556 hasRelatedWork W2127290231 @default.
• W2577208556 hasRelatedWork W2132319632 @default.
• W2577208556 hasRelatedWork W2355593916 @default.
• W2577208556 hasRelatedWork W2591860917 @default.
• W2577208556 hasRelatedWork W3082283653 @default.
• W2577208556 hasRelatedWork W3195913085 @default.
• W2577208556 isParatext "false" @default.
• W2577208556 isRetracted "false" @default.
• W2577208556 magId "2577208556" @default.
• W2577208556 workType "article" @default.